Literature DB >> 19574547

Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency.

Steven Marston1, O'Neal Copeland, Adam Jacques, Karen Livesey, Victor Tsang, William J McKenna, Shapour Jalilzadeh, Sebastian Carballo, Charles Redwood, Hugh Watkins.   

Abstract

RATIONALE: Most sarcomere gene mutations that cause hypertrophic cardiomyopathy are missense alleles that encode dominant negative proteins. The potential exceptions are mutations in the MYBPC3 gene (encoding cardiac myosin-binding protein-C [MyBP-C]), which frequently encode truncated proteins.
OBJECTIVE: We sought to determine whether there was evidence of haploinsufficiency in hypertrophic cardiomyopathy caused by MYBPC3 mutations by comparing left ventricular muscle from patients undergoing surgical myectomy with samples from donor hearts. METHODS AND
RESULTS: MyBP-C protein and mRNA levels were quantitated using immunoblotting and RT-PCR. Nine of 37 myectomy samples had mutations in MYBPC3: 2 missense alleles (Glu258Lys, Arg502Trp) and 7 premature terminations. No specific truncated MyBP-C peptides were detected in whole muscle homogenates of hypertrophic cardiomyopathy tissue. However, the overall level of MyBP-C in myofibrils was significantly reduced (P<0.0005) in tissue containing either a truncation or missense MYBPC3 mutation: 0.76+/-0.03 compared with 1.00+/-0.05 in donor and 1.01+/-0.06 in non-MYBPC3 mutant myectomies.
CONCLUSIONS: The absence of any detectable truncated MyBP-C argues against its incorporation in the myofiber and any dominant negative effect. In contrast, the lowered relative level of full length protein in both truncation and missense MYBPC3 mutations argues strongly that haploinsufficiency is sufficient to cause the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574547     DOI: 10.1161/CIRCRESAHA.109.202440

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  112 in total

1.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

Review 2.  A new era in clinical genetic testing for hypertrophic cardiomyopathy.

Authors:  Matthew Wheeler; Aleksandra Pavlovic; Emil DeGoma; Heidi Salisbury; Colleen Brown; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-30       Impact factor: 4.132

3.  A low prevalence of MYH7/MYBPC3 mutations among familial hypertrophic cardiomyopathy patients in India.

Authors:  Murali D Bashyam; Guroji Purushotham; Ajay K Chaudhary; Katika Madhumohan Rao; Vishal Acharya; Tabrez A Mohammad; Hampapathalu A Nagarajaram; Vuppaladadhiam Hariram; Calambur Narasimhan
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

Review 4.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

Review 5.  MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.

Authors:  Diederik W D Kuster; Sakthivel Sadayappan
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

Review 6.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

7.  Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

Authors:  Diederik W D Kuster; Thomas L Lynch; David Y Barefield; Mayandi Sivaguru; Gina Kuffel; Michael J Zilliox; Kyoung Hwan Lee; Roger Craig; Rajasekaran Namakkal-Soorappan; Sakthivel Sadayappan
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

8.  In vivo and in vitro cardiac responses to beta-adrenergic stimulation in volume-overload heart failure.

Authors:  Anuradha Guggilam; Kirk R Hutchinson; T Aaron West; Amy P Kelly; Maarten L Galantowicz; Amy J Davidoff; Sakthivel Sadayappan; Pamela A Lucchesi
Journal:  J Mol Cell Cardiol       Date:  2012-12-07       Impact factor: 5.000

Review 9.  Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.

Authors:  Amelia A Glazier; Andrea Thompson; Sharlene M Day
Journal:  Pflugers Arch       Date:  2018-11-20       Impact factor: 3.657

Review 10.  Phosphorylation and function of cardiac myosin binding protein-C in health and disease.

Authors:  David Barefield; Sakthivel Sadayappan
Journal:  J Mol Cell Cardiol       Date:  2009-12-03       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.